Group 1: Investor Relations Activity - The investor relations activity involved specific targeted research with participation from various fund management companies and securities firms [2][3]. - The meeting was held online on a Thursday morning, with a duration of 50 minutes [2]. Group 2: Employee Stock Ownership Plan - The company disclosed a draft for an employee stock ownership plan aiming to raise a total of CNY 33.608 million, involving directors, senior management, and core employees [3]. - The performance assessment period for the plan is set from 2026 to 2028, with specific revenue and profit targets: - Revenue targets: CNY 1 billion in 2026, CNY 1.5 billion in 2027, and CNY 2 billion in 2028 - Profit targets: CNY 300 million in 2026, CNY 500 million in 2027, and CNY 800 million in 2028 [3][4]. Group 3: Product Development and Market Strategy - The company has several core products expected to be approved or submitted for approval, including "Aitinglie" and "Lidocaine" aerosol, with anticipated revenue growth from existing products and new approvals [4][5]. - The company is actively promoting the "Hewei Zhengchang Wan" product through various media channels and expanding its sales through clinics and online platforms [5][8]. - The company plans to enhance brand promotion and has established a dedicated team for third-party channels, focusing on clinics and internet hospitals [8]. Group 4: Alzheimer's Disease Research - The company is developing CKBA for Alzheimer's disease, which has shown promising results in animal models, including cognitive improvement and reduced neuroinflammation [6][7]. - CKBA's mechanism targets MFE-2, a key enzyme in lipid metabolism, which is crucial for maintaining the homeostasis of microglial cells [7]. Group 5: Clinical Trials and Market Potential - The company is prioritizing the registration of treatments for pediatric vitiligo and rosacea, with rosacea expected to progress faster due to a shorter treatment cycle [9][10]. - The domestic market for pediatric vitiligo is significant, with no existing treatments approved by the FDA, indicating potential for market expansion [11]. Group 6: Forward-Looking Statements - The report includes forward-looking statements regarding future plans and performance forecasts, emphasizing the need for investors to recognize associated risks [11].

当日关注点 来自交易信息汇总：1月20日主力资金净流入4670.78万元，显示主力对兴齐眼药的积极介入。 交易信息汇总资金流向 截至2026年1月20日收盘，兴齐眼药(300573)报收于81.38元，上涨1.81%，换手率7.65%，成交量14.49万 手，成交额11.62亿元。 董秘最新回复 投资者： 你好，董秘，我是一直坚定投资兴齐眼的投资者，我想问一下，兴齐眼药，属于儿童用药， 可以走优先审批的路线，贵公司是否有考虑？优先纳入医保，而且现在有独家的优势，价格谈判起来会 更加的容易，为了加速提高渗透率的角度去考虑，还是说贵公司会继续先观望，请问公司在争取医保这 件事的是怎么看待的 董秘： 尊敬的投资者您好，公司将根据国家医保政策并结合市场情况做出合适的决策。感谢您的关 注。 投资者： 我想问一下，贵公司什么时候会开展国际路线，是否有打算同步开展，在欧美市场，0.01%阿 托品在美国开启临床试验，同步申请欧盟EMA注册；2027年争取获批，进入全球最大近视防控市场， 请问是否有这方面的考量？ 董秘： 尊敬的投资者您好，公司当前主营业务聚焦于国内市场，相关海外合作事宜尚处于沟通洽谈阶 段，达到信息披露节点时 ...

Group 1 - The core point of the article is that XuanZhu Bio-B (02575) saw its stock price rise over 5%, reaching a high of 71.9 HKD, approaching its historical peak of 72 HKD, following the inclusion of its innovative drug, Pyrocilin, in the national basic medical insurance drug list [1] - The inclusion of Pyrocilin in the insurance list is expected to enhance its affordability and accessibility for patients, thereby promoting the drug's market penetration and sales growth, which will positively impact the long-term operational development of XuanZhu Bio [1] - Pyrocilin, a new CDK2/4/6 inhibitor, has shown strong efficacy in inhibiting tumor cell proliferation and was approved by the National Medical Products Administration of China for specific types of advanced or metastatic breast cancer patients in May 2025 [1] Group 2 - Both approved indications for Pyrocilin have been included in the 2025 national basic medical insurance directory, and an application for its use in first-line treatment in combination with aromatase inhibitors is currently under review [1]

Group 1 - The core point of the article is that 基石药业's drug, 普吉华 (普拉替尼胶囊, 100mg), has been included in the latest National Medical Insurance Drug List in China, which will take effect on January 1, 2026 [1] - Following the announcement, 基石药业's stock price increased by over 4%, with a current price of 5.82 HKD and a trading volume of 24.98 million HKD [1] - Additionally, non-executive director 胡正国 purchased 1 million shares of 基石药业 at a price of 5.7546 HKD per share, totaling 5.7546 million HKD, increasing his holdings to 3.471 million shares, representing 0.24% of the company [1]

Core Viewpoint - UBS reports that Innovent Biologics (01801) has six new products and a new indication for sintilimab included in the latest National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List (2025) [1] - Innovent Biologics has been officially included in the Hang Seng Index as of today [1] - UBS maintains a "Buy" rating with a target price of HKD 137.4 [1] Group 1 - The new products targeting IGF-1R, EGFR, BTK, ROS1, KRAS G12C, and RET are expected to see rapid sales growth by 2026 [1] - The inclusion of teriparatide for diabetes in the insurance list positively impacts the expected launch of masitinib in 2026, although price adjustments need to be monitored [1] - Inclusion in the Hang Seng Index is anticipated to further enhance liquidity for the company's stock [1]

Major Events - GuoXia Technology (02655) plans to conduct an IPO from December 8 to December 11, offering 33.85 million H-shares and introducing cornerstone investors such as Huikai Hong Kong [1] - Basilea Pharmaceutica AG (02616) has its drug Pujihua® (Pralsetinib Capsules) included in the National Medical Insurance Directory for 2025 [1] - Four Seasons Pharmaceutical (00460) sees its innovative drug XuanYueNing® included in the National Basic Medical Insurance Drug List for the first time [1] - Shanghai Pharmaceuticals (02607) successfully negotiates and includes Amisulpride Orally Disintegrating Tablets in the National Medical Insurance Directory [1] - Hansoh Pharmaceutical (03692) has its innovative drug Amelotex® approved for two new indications in the updated 2025 National Medical Insurance Directory [1] - Xiansheng Pharmaceutical (02096) sees EnzeShu® and EnDu® included in the updated National Medical Insurance Drug List [1] - Hutchison China MediTech (00013) has its drug Tazverik® included in the first edition of the National Commercial Health Insurance Innovative Drug List [1] - XuanZhu Biotechnology (02575) has its innovative drug XuanYueNing® included in the National Basic Medical Insurance Drug List for the first time [1] - Yino Pharmaceutical (02591) has its H-shares included in the list of eligible securities for the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect [1] - China Metallurgical Group (01618) and its subsidiaries plan to sell non-core business assets for approximately 60.68 billion yuan, focusing on core businesses in metallurgical engineering, non-ferrous metals, and mining engineering [1] - Cambridge Technology (06166) intends to invest a total of 405 million yuan to acquire and subscribe for shares in the Yangzhong Happiness Home Venture Capital Partnership Fund [1] Operating Performance - Dongfeng Motor Group (00489) reports cumulative automobile sales of 1.697 million units in the first 11 months, a year-on-year decrease of approximately 0.3% [2] - New天绿色能源 (00956) achieves a cumulative power generation of 1,336.89 million MWh in the first 11 months, an increase of 8.04% year-on-year [2] - Longyuan Power (00916) reports a cumulative power generation of approximately 6,909.64 million MWh in the first 11 months, a year-on-year growth of 0.41% [2] - Baolong Real Estate (01238) records a total contract sales of approximately 6.666 billion yuan in the first 11 months, a year-on-year decline of 43.2% [2]

Core Viewpoint - The inclusion of the drug Praluent® (Pralsetinib capsules, 100 mg) in China's National Medical Insurance Catalog is a significant development for the company, as it will officially take effect on January 1, 2026, enhancing the drug's market access and potential sales in the region [1] Group 1: Drug Approval and Indications - Praluent® is an oral targeted therapy approved by the National Medical Products Administration (NMPA) for treating adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who are RET gene fusion positive, as well as for adult and pediatric patients aged 12 and above with advanced or metastatic RET mutation medullary thyroid carcinoma (MTC) requiring systemic treatment [1] - The drug has also been approved in Hong Kong for treating adult patients with metastatic RET fusion-positive NSCLC and in Taiwan for similar indications, including advanced or metastatic RET fusion-positive thyroid cancer [1] Group 2: Commercialization and Partnerships - The drug Praluent® is developed by Blueprint Medicines, which was acquired by Sanofi in July 2025, while the company holds exclusive development and commercialization rights for Praluent® in Greater China, including mainland China, Hong Kong, Macau, and Taiwan [2] - In November 2023, the company granted exclusive commercialization rights for Praluent® in mainland China to Shanghai Elios Pharmaceutical Technology Co., Ltd [2]

（股份代號：2575） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 Xuanzhu Biopharmaceutical Co., Ltd. 軒竹生物科技股份有限公司 （一家於中華人民共和國註冊成立的股份有限公司） 吡 洛 西 利 片（商 品 名：軒 悅 寧®）作 為 新 型CDK2/4/6抑 製 劑，具 有 獨 特 的 多 靶 點 協 同 作 用 機 制，具 有 強 效 抑 制 腫 瘤 細 胞 增 殖，顯 著 降 低 傳 統CDK4/6抑製劑常見的 血 液 學 毒 性 等 優 勢。吡 洛 西 利 已 於 二 零 二 五 年 五 月 獲 得 中 國 國 家 藥 品 監 督 管 理局批准與氟維司群聯合用於既往接受內分泌治療後出現疾病進展的激素受 體陽性(HR+)、人 表 皮 生 長 因 子 受 體2陰 性(HER2-)（「HR+╱HER2-」）晚 期 或 轉 移 性 乳 腺 癌 患 者；單 藥 ...

Core Viewpoint - The stock of Innovent Biologics (01801) has experienced a significant decline of over 6%, currently trading at 87 HKD with a transaction volume of 1.86 billion HKD, despite the inclusion of seven innovative products in the new medical insurance directory [1] Group 1: Product Developments - Innovent Biologics has successfully included seven innovative products, including the PD-1 inhibitor Tyvyt (sintilimab injection), in the new medical insurance directory, expanding the indications for mature products [1] - With the recent additions, all eight approved indications for Tyvyt are now covered by medical insurance, which may enhance market access and patient affordability [1] Group 2: Financial Transactions - The company has completed a share issuance to Takeda Pharmaceutical, issuing 6.9138 million shares, which represents approximately 0.4% of the total issued share capital, raising nearly 780 million HKD in net proceeds [1] - There have been significant large transactions in the market, involving approximately 13.0734 million shares at an average price of 92 HKD per share, totaling over 1.2 billion HKD [1]

Core Viewpoint - Haichuang Pharmaceutical's drug, Deuteroenzalutamide soft capsule, has been included in the 2025 National Medical Insurance Drug List, effective from January 1, 2026, following successful negotiations with the National Healthcare Security Administration and the Ministry of Human Resources and Social Security [2][6]. Drug Information - The drug's generic name is Deuteroenzalutamide soft capsule, marketed as Hainan An, classified as a Category B drug under the medical insurance system, with an agreement validity from January 1, 2026, to December 31, 2027 [3]. - Deuteroenzalutamide is a first-class new drug developed for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and is a second-generation androgen receptor (AR) inhibitor, supported by the National Major New Drug Creation Technology Major Project [3]. - Clinical data from Phase III trials showed that Deuteroenzalutamide significantly extended progression-free survival (PFS) by reducing the risk of disease progression or death by 42% compared to the control group (HR=0.58, 95% CI: 0.439-0.770; p=0.0001) [3]. - The drug is the first domestically approved innovative treatment for adult patients with mCRPC who have progressed after receiving abiraterone acetate and chemotherapy, and it demonstrates superior safety by significantly reducing the incidence of central nervous system adverse events [3]. Market Context - Prostate cancer ranks as the second most common malignancy among men globally, with 1.467 million new cases reported in 2022, and in China, the incidence reached 134,000 new cases in the same year [4]. - The market for prostate cancer treatments in China is projected to reach 50 billion yuan by 2030, with the second-generation anti-androgen drug market expected to exceed 4 billion yuan by 2024 [4]. - Endocrine therapy remains the recommended first-line treatment for metastatic castration-resistant prostate cancer [4]. Company Impact - The inclusion of Deuteroenzalutamide in the National Medical Insurance Drug List reflects the recognition of its clinical value and innovation, facilitating market promotion and reducing patient medication costs [6]. - The company plans to actively support the implementation of insurance policies and expand hospital access to meet patient needs [6].